Literature DB >> 28830617

Cancer-promoting mechanisms of tumor-associated neutrophils.

Brian Hurt1, Richard Schulick1, Barish Edil1, Karim C El Kasmi2, Carlton Barnett3.   

Abstract

IMPORTANCE: Neutrophils have classically been considered to mount a defensive response against tumor cells, yet recent evidence suggests tumors modulate neutrophil function to support tumor growth and progression. OBSERVATIONS: Tumor-associated neutrophils (TANs) are phenotypically distinct from circulating neutrophils in terms of their surface protein composition and cyto/chemokine activity and response. Although TANs have been shown to both promote and inhibit tumor advancement, the preponderant activity augments tumor progression. This review discusses these cancer-promoting molecular pathways, relevant diagnostic studies in patients, and subsequent treatment modalities. The tumor promoting mechanisms of TANs include dampening of CD8+ response via Arginase-1; a neutrophil-secreted neutrophil elastase (NE) upregulation of tumor cellular proliferation pathways; degradation of basement membrane and ECM via NE and MMP-9; upregulation of angiogenesis by VEGF, and HGF; and ICAM-1 dependent tumor intravasation, immune protection in circulation, and extravasation into distant, metastatic tissue beds. Clinicians are constrained in treating TANs systemically as it may induce neutropenia, therefore targeting TANs-mediated tumor progression pathways surgically on a loco-regional level is a viable adjuvant treatment modality. CONCLUSION AND RELEVANCE: TANs modulate the tumor microenvironment promoting tumor progression. Mechanistic understanding of TANs role in tumor progression will provide unique therapeutic alternatives. Published by Elsevier Inc.

Entities:  

Keywords:  Chemokines; Cytokines; Immunomodulation; Metastasis; Tumor microenvironment; Tumor progression; Tumor-associated neutrophils

Mesh:

Year:  2017        PMID: 28830617     DOI: 10.1016/j.amjsurg.2017.08.003

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  43 in total

1.  Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth.

Authors:  Udayan Bhattacharya; Lilach Gutter-Kapon; Tal Kan; Ilanit Boyango; Uri Barash; Shi-Ming Yang; JingJing Liu; Miriam Gross-Cohen; Ralph D Sanderson; Yuval Shaked; Neta Ilan; Israel Vlodavsky
Journal:  Cancer Res       Date:  2019-11-05       Impact factor: 12.701

2.  Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma.

Authors:  Guen Tae Kim; Eun Young Kim; Su-Hyun Shin; Hyowon Lee; Se Hee Lee; Ki-Young Sohn; Jae Wha Kim
Journal:  BMC Cancer       Date:  2022-07-04       Impact factor: 4.638

Review 3.  Myeloid-derived suppressor cells coming of age.

Authors:  Filippo Veglia; Michela Perego; Dmitry Gabrilovich
Journal:  Nat Immunol       Date:  2018-01-18       Impact factor: 25.606

4.  Interleukin-8 Receptor 2 (IL-8R2)-Deficient Mice Are More Resistant to Pulmonary Coccidioidomycosis than Control Mice.

Authors:  Aaron F Carlin; Suganya Viriyakosol; Sharon Okamoto; Lorraine Walls; Joshua Fierer
Journal:  Infect Immun       Date:  2020-12-15       Impact factor: 3.441

Review 5.  Solid Tumors Challenges and New Insights of CAR T Cell Engineering.

Authors:  Safa Tahmasebi; Reza Elahi; Abdolreza Esmaeilzadeh
Journal:  Stem Cell Rev Rep       Date:  2019-10       Impact factor: 5.739

Review 6.  Neutrophils: fast and furious-the nucleotide pathway.

Authors:  Dominique S Rubenich; Priscila O de Souza; Natalia Omizzollo; Gabriela S Lenz; Jean Sevigny; Elizandra Braganhol
Journal:  Purinergic Signal       Date:  2021-04-29       Impact factor: 3.765

Review 7.  Exosomes Promote Pre-Metastatic Niche Formation in Gastric Cancer.

Authors:  Jing Gao; Song Li; Qian Xu; Xue Zhang; Miao Huang; Xin Dai; Lian Liu
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

8.  Combining Preoperative and Postoperative Inflammatory Indicators Can Better Predict the Recurrence of Hepatocellular Carcinoma After Partial Hepatectomy.

Authors:  Meilong Wu; Shizhong Yang; Xiaobin Feng; Chengquan Li; Xiangchen Liu; Zhenyu Zhang; Ying Xiao; Chuchu Liu; Jiahong Dong
Journal:  J Inflamm Res       Date:  2021-07-13

Review 9.  Overcoming Barriers of Age to Enhance Efficacy of Cancer Immunotherapy: The Clout of the Extracellular Matrix.

Authors:  Mark Owyong; Gizem Efe; Michael Owyong; Aamna J Abbasi; Vaishnavi Sitarama; Vicki Plaks
Journal:  Front Cell Dev Biol       Date:  2018-03-01

10.  Novel natural killer cell-mediated cancer immunotherapeutic activity of anisomycin against hepatocellular carcinoma cells.

Authors:  Miok Kim; Seon-Jin Lee; Sangsu Shin; Kang-Seo Park; Sang Yoon Park; Chang Hoon Lee
Journal:  Sci Rep       Date:  2018-07-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.